Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$40.53 - $75.71
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.72M
Market Cap
$5.45B
Enterprise Value$5.99B
Total Cash (Recent Filing)$42.26M
Total Debt (Recent Filing)$42.41M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 01, 2025EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding118,410,690
10 Day Avg. Volume2,079,207
30 Day Avg. Volume1,724,307
Standard Deviation0.24
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1739.60
Price to Cash Flow (P/CF)-13.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.57
Enterprise Value/Ebitda-12.37
Forecast
1Y Price Target
$81.64Price Target Upside77.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
CollaborationsThe company received a $15M upfront payment related to the transfer of aficamten commercialization rights to Sanofi, indicating strong collaborative support.
Regulatory ApprovalsCytokinetics expects the approval of aficamten for obstructive hypertrophic cardiomyopathy by the FDA, which could lead to better sales and ramp.
Bears Say
Operational ChallengesExecution is unlikely to be straightforward, particularly given the logistical challenges administering CMIs.
---
Ownership Overview
0.76% Insiders
37.56% Mutual Funds
0.14% Other Institutional Investors
38.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $40.53 and its highest was $75.71 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $5.45B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is May 01, 2025 which is in 59 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Feb 27, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.193 by -$0.067.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.34.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 118,410,690 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.193. Following the earnings report the stock price went down -3.056%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.64 (77.48% Upside)
$81.64 (77.48% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 104.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $874.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.06%
12-Months-Change
Fundamentals
Return on Equity
4143.50%
Trailing 12-Months
Asset Growth
70.04%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory progress and strategic partnerships for aficamten, a strong financial position, and pipeline advancements. However, increased expenses and ongoing regulatory challenges were noted. Despite these challenges, the progress and strategic moves position the company well for future growth.Read More>---
CYTK Stock 12 Month Forecast
Average Price Target
$81.64
▲(77.48% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+88.48%
upgraded a buy rating 19 days ago
Copying Jeffrey Hung's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +88.48% per trade.
---